New PSMA radiotracers comparative study (01/01/2020)

IMHO, a point of interest for patient information/guidance is summarized in Table 3.

"18F DCFPyL......Very low hepatic uptake, which allows for the detection of small liver lesions [14] May be of value in later stages of disease [51]....."

"18F PSMA-1007..... Higher hepatic background, which may be a drawback in later stages of disease (for the detection of liver lesions) [51].....Very low radiotracer accumulation in the urinary system, which renders this imaging agent an attractive alternative to identify small lesions in the pelvis or for local recurrence [69]"

"18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging"

thno.org/v10p0001.pdf

[Claud68]

Thank you! Very interesting.